An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter”Bchl-D) for use in combination therapy for cancer. wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).